EA201692404A1 - Пептиды, выполняющие роль агонистов окситоцина - Google Patents
Пептиды, выполняющие роль агонистов окситоцинаInfo
- Publication number
- EA201692404A1 EA201692404A1 EA201692404A EA201692404A EA201692404A1 EA 201692404 A1 EA201692404 A1 EA 201692404A1 EA 201692404 A EA201692404 A EA 201692404A EA 201692404 A EA201692404 A EA 201692404A EA 201692404 A1 EA201692404 A1 EA 201692404A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- hydrogen
- lower alkyl
- cycloalkyl
- chr
- atom
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Addiction (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
Изобретение относится к соединениям формулыгде Rявляется водородом, низшим алкилом или циклоалкилом; Rявляется водородом или Rи Rмогут образовывать вместе с атомом N и атомом С, к которым они присоединены, пирролидиновое кольцо, необязательно замещенное одним или двумя атомами F или гидроксильной группой, или могут образовывать азетидиновое или пиперазиновое кольцо; Rявляется водородом, низшим алкилом, низшим алкилом, замещенным гидроксильной группой, -(CH)C(O)NH, бензилом, фенилом, -СН-пятичленной ароматической гетероциклической группой, СН-индолилом, -СН-циклоалкилом, циклоалкилом или -(СН)-S-низшим алкилом; Rявляется водородом или низшим алкилом; или X представляет собой -C(O)-CHR-CHR-C(O)-NH-CH-, R/Rявляются водородом, или один из Rили Rпредставляет собой аминогруппу; о означает 0 или 1; или к их фармацевтически приемлемой соли присоединения кислоты, к рацемической смеси или к его соответствующему энантиомеру и/или его оптическим изомерам. Было установлено, что настоящие соединения являются агонистами окситоциновых рецепторов для лечения аутизма, стресса, включая посттравматическое стрессовое расстройство, тревоги, включая тревожные расстройства и депрессию, шизофрении, психических расстройств и потери памяти, алкогольной абстиненции, лекарственной зависимости, а также для лечения синдрома Прадера-Вилли.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14170992 | 2014-06-03 | ||
PCT/EP2015/062054 WO2015185467A1 (en) | 2014-06-03 | 2015-06-01 | Peptides as oxytocin agonists |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201692404A1 true EA201692404A1 (ru) | 2017-05-31 |
EA030091B1 EA030091B1 (ru) | 2018-06-29 |
Family
ID=50842169
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201692404A EA030091B1 (ru) | 2014-06-03 | 2015-06-01 | Пептиды, выполняющие роль агонистов окситоцина |
Country Status (16)
Country | Link |
---|---|
US (1) | US9957298B2 (ru) |
EP (1) | EP3151849B1 (ru) |
JP (1) | JP6412170B2 (ru) |
KR (1) | KR20170004013A (ru) |
CN (1) | CN106414479B (ru) |
AU (1) | AU2015270723A1 (ru) |
CA (1) | CA2949173A1 (ru) |
CL (1) | CL2016003095A1 (ru) |
CR (1) | CR20160563A (ru) |
EA (1) | EA030091B1 (ru) |
IL (1) | IL248553A0 (ru) |
MX (1) | MX2016015873A (ru) |
PE (1) | PE20161559A1 (ru) |
PH (1) | PH12016502232A1 (ru) |
SG (1) | SG11201610073PA (ru) |
WO (1) | WO2015185467A1 (ru) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI3666258T1 (sl) | 2014-09-19 | 2024-04-30 | Ferring Bv | Postopek zdravljenja Prader-Willijevega sindroma |
WO2019060962A1 (en) * | 2017-09-28 | 2019-04-04 | The University Of Sydney | SELECTIVE AGONISTS OF THE OCYTOCIN RECEPTOR, INSPIRED BY METABOLITES |
EP3852723A4 (en) * | 2018-09-20 | 2022-06-29 | Levo Therapeutics, Inc. | Stable intranasal formulations of carbetocin |
TW202034899A (zh) | 2018-09-20 | 2020-10-01 | 克里斯托弗 S 布萊恩特 | 卡貝縮宮素藥品及其製備方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9701162D0 (sv) * | 1997-03-27 | 1997-03-27 | Karolinska Innovations Ab | New use II |
KR20070022753A (ko) * | 2004-05-26 | 2007-02-27 | 화이자 인코포레이티드 | 인다졸 및 인돌론 유도체 및 이의 약제로서의 용도 |
EA026578B1 (ru) * | 2007-01-22 | 2017-04-28 | ДЖиТиЭкс, ИНК. | Вещества, связывающие ядерные рецепторы |
EP2260053B1 (en) * | 2008-03-31 | 2014-05-14 | Ferring BV | Oxytocin analogues |
WO2010034656A1 (en) * | 2008-09-23 | 2010-04-01 | F. Hoffmann-La Roche Ag | Isoxazolo[4,5]pyridin-3-yl-piperazin derivatives useful as modulatorsof dopamine d3 receptors |
MX2011011477A (es) * | 2009-05-05 | 2011-11-18 | Hoffmann La Roche | Derivados de isoxazol-piridazina. |
TWI463990B (zh) * | 2009-09-21 | 2014-12-11 | Ferring Bv | 催產素受體促進劑 |
EP2482835B1 (en) * | 2009-10-01 | 2014-07-02 | The University Of Sydney | Therapy and prevention of problem drinking |
DK2935312T3 (en) | 2012-12-21 | 2018-10-22 | Hoffmann La Roche | Peptides as oxytocin agonists |
-
2015
- 2015-06-01 CA CA2949173A patent/CA2949173A1/en not_active Abandoned
- 2015-06-01 JP JP2016571027A patent/JP6412170B2/ja not_active Expired - Fee Related
- 2015-06-01 AU AU2015270723A patent/AU2015270723A1/en not_active Abandoned
- 2015-06-01 SG SG11201610073PA patent/SG11201610073PA/en unknown
- 2015-06-01 CR CR20160563A patent/CR20160563A/es unknown
- 2015-06-01 WO PCT/EP2015/062054 patent/WO2015185467A1/en active Application Filing
- 2015-06-01 EA EA201692404A patent/EA030091B1/ru not_active IP Right Cessation
- 2015-06-01 MX MX2016015873A patent/MX2016015873A/es unknown
- 2015-06-01 PE PE2016002397A patent/PE20161559A1/es unknown
- 2015-06-01 CN CN201580027370.7A patent/CN106414479B/zh not_active Expired - Fee Related
- 2015-06-01 KR KR1020167036060A patent/KR20170004013A/ko not_active Application Discontinuation
- 2015-06-01 EP EP15725359.2A patent/EP3151849B1/en not_active Not-in-force
-
2016
- 2016-10-27 IL IL248553A patent/IL248553A0/en unknown
- 2016-11-09 PH PH12016502232A patent/PH12016502232A1/en unknown
- 2016-12-01 CL CL2016003095A patent/CL2016003095A1/es unknown
- 2016-12-02 US US15/368,080 patent/US9957298B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN106414479A (zh) | 2017-02-15 |
AU2015270723A1 (en) | 2016-11-17 |
US9957298B2 (en) | 2018-05-01 |
SG11201610073PA (en) | 2016-12-29 |
WO2015185467A1 (en) | 2015-12-10 |
CL2016003095A1 (es) | 2017-06-16 |
EP3151849B1 (en) | 2018-10-10 |
KR20170004013A (ko) | 2017-01-10 |
US20170081369A1 (en) | 2017-03-23 |
JP6412170B2 (ja) | 2018-10-24 |
CN106414479B (zh) | 2021-08-03 |
PH12016502232A1 (en) | 2017-01-09 |
PE20161559A1 (es) | 2017-01-12 |
EA030091B1 (ru) | 2018-06-29 |
CA2949173A1 (en) | 2015-12-10 |
IL248553A0 (en) | 2016-12-29 |
EP3151849A1 (en) | 2017-04-12 |
CR20160563A (es) | 2017-01-06 |
JP2017518311A (ja) | 2017-07-06 |
MX2016015873A (es) | 2017-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201591078A1 (ru) | Пептиды в качестве агонистов окситоцина | |
AR096640A1 (es) | Derivados de indolin-2-ona o pirrolo-piridin / pirimidin-2-ona | |
CL2018000036A1 (es) | Derivados etinilo | |
EA201692488A1 (ru) | Пептиды, выполняющие роль агонистов окситоцина | |
PH12016502231B1 (en) | Indolin-2-one or pyrrolo-pyridin-2-one derivatives | |
EA201592146A1 (ru) | Гетероароматические соединения и их применение в качестве лигандов к дофаминовым d1-рецепторам | |
EA201492170A1 (ru) | Новые замещенные в цикле n-пиридиниламиды в качестве ингибиторов киназ | |
EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
ECSP14013221A (es) | Fenil-3-aza-biciclo [3.1.0] hex-3-il-metanonas y su uso como medicamento. | |
AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
EA201590438A1 (ru) | 2-оксо-2,3-дигидроиндолы для лечения расстройств центральной нервной системы | |
PE20181853A1 (es) | 1,5-dihidro-4h-pirazolo[3,4-d]pirimidin-4-onas y 1,5-dihidro-4h-pirazolo[4,3-c]piridin-4-onas como inhibidores de pde1 | |
BR112015014687A2 (pt) | compostos de piridazina bicíclicos fundidos substituídos por arila | |
EA201692404A1 (ru) | Пептиды, выполняющие роль агонистов окситоцина | |
EA201691046A1 (ru) | Производные этинилимидазолин-2,4-диона в качестве модуляторов метаботропного глутаматного рецептора 4 (mglur4) | |
EA201391537A1 (ru) | ЭТИНИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ mGluR5 | |
AR097721A1 (es) | Derivados de etinilo | |
EA201691831A1 (ru) | Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов | |
BR112016017816A8 (pt) | derivados de etinila, seus usos, e composição farmacêutica | |
EA201691788A1 (ru) | Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов | |
CY1118595T1 (el) | Αρυλοαιθινυλο πυριμιδινες | |
BR112015002320A2 (pt) | derivados de etinila como moduladores de atividade de receptor mglur5 | |
BR112015007991A2 (pt) | derivados de etinila como moduladores da atividade do receptor de mglur5 | |
BR112016024149A2 (pt) | derivados de indolin-2-ona e 1,3-di-hidro-pirrol[3,2-c]piridin-2-ona | |
TH167739B (th) | เปปไทด์เป็นตัวทำการออกซีโทซิน |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM RU |